New drug candidate BL-M02D1 tested in patients with advanced cancers
NCT ID NCT05385692
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This early-phase study tests a new drug called BL-M02D1 in 22 adults with advanced gastrointestinal or other solid tumors that cannot be cured or have no standard treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants receive the drug by injection and are closely monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.